Graegis Pharmaceuticals

Name

Graegis Pharmaceuticals

Legal name

Graegis Pharmaceuticals

Website

https://graegis.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Oncology Supportive Care Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Radiation dermatitis prevention
• Oncology supportive care
• Radiation therapy skincare
• Dermatological protection products
• Cancer therapy skin care

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Marketing or Sales, Personnel

Core offering

Graegis Pharmaceuticals develops dermatological products designed to prevent radiation-induced skin damage in patients undergoing radiation therapy (RT) for cancer treatment. The company's offering is positioned to integrate seamlessly into the patient treatment journey, focusing on true prevention of radiation damage rather than treatment of existing damage.

Differentiator

Problem solved

Functional benefit

Products and services

• Radiation Skin Protection Therapy

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Alys PharmaceuticalscoreOthersGraegis Pharmaceuticals is now a fully owned subsidiary of Alys Pharmaceuticals. This represents a corporate acquisition/ownership relationship where Graegis operates as part of the Alys Pharmaceuticals corporate group.

Broad incumbents

• Almirall: European specialty pharmaceutical company with a strong dermatology franchise across multiple skin conditions. Comparable as a larger, established dermatology-focused pharma operating in the same prescription skincare category.
• Bayer Consumer Health: Large consumer health and pharmaceutical company with dermatology and skin-care product lines. Comparable as a broad incumbent with skin-protection consumer and OTC products relevant to sensitive or compromised skin.
• Sun Pharmaceutical Industries: Global specialty pharmaceutical company with a substantial dermatology and oncology product portfolio. Comparable as a broad incumbent with overlapping dermatology pharmaceutical capabilities.

Direct peers

• Galderma: Global specialty dermatology pharmaceutical company with prescription and aesthetic products across skin conditions. Directly comparable because Graegis is also developing a prescription-style dermatology product aimed at a specific skin indication (radiation-induced skin damage).
• Aclaris Therapeutics: Clinical-stage dermatology pharmaceutical company developing novel prescription therapies for skin and immune-mediated conditions. Comparable to Graegis as a small-cap, innovation-driven dermatology pharma.
• Dermavant Sciences: Specialty dermatology pharmaceutical company developing prescription therapies for inflammatory and other skin conditions. Comparable in being a focused dermatology pharma with a niche, clinically differentiated positioning versus broader players.
• LEO Pharma: Specialty dermatology pharmaceutical company focused on prescription treatments for skin diseases. Comparable to Graegis as a prescription dermatology-focused pharma targeting an underserved skin condition.
• Soligenix: Late-stage biopharmaceutical company developing treatments for rare diseases including oncology supportive care indications. Comparable because both target supportive-care needs in oncology patients with specialized products.
• Helsinn: Specialty pharmaceutical company focused on supportive care in oncology and cancer-related conditions. Comparable to Graegis because both develop supportive-care products used alongside cancer treatment to address side effects such as skin toxicity.

Others

• Novocure: Commercial-stage oncology company whose primary product (Tumor Treating Fields) is used alongside radiation and other cancer therapies. Comparable as a company whose products are administered in conjunction with radiation therapy to improve cancer treatment outcomes.

Market position

Customer concentration

• LinkedInlinkedin.com/company/graegis-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Graegis Pharmaceuticals